FDA Authorized Reduced-Risk Claims for ZYN Pouches

The agency approved modified-risk marketing orders for 20 ZYN products on June 30, 2026.

Updated on Sept. 29, 2026 in Nutrition

Bold flat-color editorial illustration of a simple circular canister on a flat surface, symbolizing federal health regulatory policy. — The FDA authorized Swedish Match USA to market 20 ZYN nicotine products with reduced-risk claims, citing scientific evidence that they are less harmful than combustible cigarettes. AI Illustration. Upload story photo >

Live Poll

Do you trust FDA authorizations allowing tobacco companies to market products as reduced-risk?

The FDA issued modified-risk orders on June 30, 2026, authorizing 20 ZYN nicotine pouches to market claims that they lower the risk of six specific diseases compared to smoking cigarettes. This authorization for the manufacturer, Swedish Match USA, is valid for five years.

Why it matters

The FDA concluded that the authorized claims are scientifically accurate and provide a population-level health benefit by offering adult smokers a less risky alternative to cigarettes. The agency based its decision on a comprehensive scientific review of health risks and consumer understanding.

The FDA granted modified-risk status to 20 ZYN products following a scientific review of health data. This authorization remains valid for a duration of 5 years.

The players

FDA

The United States Food and Drug Administration is the federal agency responsible for regulating tobacco products and protecting public health.

Swedish Match USA

Swedish Match USA is the manufacturer of ZYN nicotine pouches and is subject to FDA regulatory oversight and postmarket surveillance requirements.

The details

The marketing orders permit Swedish Match USA to state that switching from cigarettes to these specific ZYN pouches reduces the risk of six diseases. To maintain this status, the manufacturer must conduct mandatory postmarket surveillance and studies, as the FDA retains the authority to withdraw the orders if they no longer benefit public health.

January 2025: The FDA first authorized the initial marketing of these 20 ZYN products.
June 30, 2026: The FDA officially issued the modified-risk marketing orders.
August 2026: The FDA authorized 11 additional ZYN ULTRA products.
September 29, 2026: The current article publication date.

The Big Picture

This regulatory decision follows the specific procedures established by the premarket tobacco product application pathway, which governs how the FDA assesses new tobacco products. This authorization represents an extension of the agency's regulatory framework for modified-risk tobacco products.

Adult smokers may encounter new marketing claims on ZYN packaging that differentiate these products from cigarettes based on reduced disease risk. Consumers should note that these specific claims do not apply to the 11 ZYN ULTRA products, which remain outside the scope of this authorization.

The takeaway

This FDA decision marks a shift in how nicotine products are permitted to communicate health-related information to the public. Users should continue to monitor official health guidance as the agency maintains its ongoing surveillance of these products.